Abstract

This project is designed to evaluate the molecular markers in patients that are undergoing radiotherapy in serum and urine. This work is prospective and hypothesis generating. In the past year we have initiated an international trial of patients with glioblastoma multiforme (GBM) to determine if urinary vascular endothelial growth factor (VEGF) or matrix metalloproteinase-2 (MMP-2) can help predict outcome. This past year we have worked on standardizing the collection procedures, analysis procedures, and the many biomolecules that could incorrectly alter the VEGF levels and we have published 2 manuscripts on specimen preparation and storage.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIASC010372-11
Application #
8350084
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2011
Total Cost
$1,106,642
Indirect Cost

  Institution

Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Krauze, Andra V; Attia, Albert; Braunstein, Steve et al. (2017) Expert consensus on re-irradiation for recurrent glioma. Radiat Oncol 12:194
Krauze, Andra Valentina; Peters, Cord; Cheng, Jason et al. (2017) Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system. Radiat Oncol 12:191
Steeg, Patricia S; Camphausen, Kevin A; Smith, Quentin R (2011) Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11:352-63
de Groot, John F; Piao, Yuji; Tran, Hai et al. (2011) Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 17:4872-81
Stall, Bronwyn; Zach, Leor; Ning, Holly et al. (2010) Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas. Radiat Oncol 5:5
Shabason, Jacob E; Camphausen, Kevin (2010) Cancer stem cells as a prognostic indicator for glioblastoma multiforme. Biomark Med 4:127-8
Shabason, Jacob E; Tofilon, Philip J; Camphausen, Kevin (2010) HDAC inhibitors in cancer care. Oncology (Williston Park) 24:180-5
Camphausen, Kevin (2009) Seminars in Radiation Oncology. Introduction. Semin Radiat Oncol 19:141
Kurshan, Naamit; Citrin, Deborah E; Camphausen, Kevin A (2009) Research highlights. Biomark Med 3:17-9
Russo, Andrea L; Jedlicka, Kimberly; Wernick, Meredith et al. (2009) Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 15:4292-8

Showing the most recent 10 out of 15 publications